We are only able to display limited information for this firm. We display more complete information for all of the following firms:
From the establishment and financing of pioneering life sciences companies to patent litigation and complex IP issues relating to projects and collaborations concerning products and services driven by AI technology, Bristows LLP is active across a wide range of work in the life sciences space. Practice co-head Liz Cohen is a seasoned patent litigator with a proven track record in co-ordinating cross-border litigation. Fellow co-head Richard Dickinson is equipped to assist clients with manufacturing and supply agreements. ‘Standout’ partner Brian Cordery is active across patent disputes for medicines used to treat conditions such as multiple sclerosis, leukaemia and heart failure, while Alex Denoon‘s regulatory expertise is sought after by clients specialising in disruptive technologies. Robert Burrows’ expertise extends to plant variety right cases for clients in the life sciences sector, and Claire Smith advises on a range of commercial partnering agreements. Adrian Chew further extends the patent disputes expertise at the firm.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘The Bristows team are a team to be reckoned with in the fields of life sciences and healthcare. They combine excellent technical knowledge with legal nous to achieve the commercial objectives of their clients, guiding them efficiently and effectively to a valuable result. ’
‘Charlie French is excellent to work with, intelligent and responsive, manages the team effectively with ease.'
Key clients
- Syncona
- Telix Pharmaceuticals
Work highlights
Advised AstraZeneca on a high profile patent deal with Chinese biotech Usynova to add to AstraZeneca’s oncology pipeline by licensing Usynova’s novel pancreatic cancer therapy in a transaction worth $420 million.
Acting for Genentech and Novartis in ongoing UK High Court revocation and infringement proceedings against Celltrion in respect of Genentech’s and Novartis’s antibody medicine Xolair (ex-US sales $1.463 billion).